A Trial Comparing the Uncovered to the Covered Wallstent in the Palliation of Malignant Bile Duct Strictures

Brigham and Women's Hospital129 enrolled

Overview

The purpose of the study is to determine the best management of bile duct narrowing (stricture) due to inoperable tumors. The bile duct is a tube that carries bile formed in the liver to the small bowel to digest fats. Tumors around the bile duct can compress the duct causing pain, jaundice (yellow skin and eyes), itchy skin and fever.

This is a prospective randomized trial conducted at 4 large teaching hospitals (Brigham and Women's Hospital, Massachusetts General Hospital, and Boston Medical Center, Boston, Massachusetts, and Mayo Clinic, Rochester, Minnesota). Malignancy is determined by pathology. Cancer stage is determined by transabdominal imaging and/or endoscopic ultrasound (EUS). Written informed consent is obtained from each of the enrolled patients. The study is approved by the Institutional Review Boards at each of the participating centers.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

DOUBLE

Enrollment

129

Conditions

Inoperable Tumors of the Bile Duct

Interventions

Partially Covered WallstentDEVICE

Partially covered wallstent

Uncovered WallstentDEVICE

Uncovered wallstent

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ≥ 18 years of age. * Malignant bile duct stricture. * Increased bilirubin. * Duct stricture is ≥ 1 cm distal to the biliary hilum (bifurcation of the common hepatic duct into the right and left hepatic ducts). * Not an operative candidate. Exclusion Criteria: * Unable to obtain consent. * Unable to tolerate procedure. * Suspected benign bile duct stricture. * Candidate for potentially curative surgical intervention. * Previous metallic biliary stent. * Previous bile duct surgery.

Outcomes

Primary Outcomes

Time to Recurrent Biliary Obstruction

Biliary obstruction is the narrowing (stricture) of the bile duct. This narrowing prevents bile, which is formed in the liver, from being carried to the small bowel to digest fats. Symptoms of biliary obstruction are pain, jaundice (yellow skin and eyes), itchy skin and fever. Time to biliary obstruction is defined as the time from the placement of the stent to the time of biliary obstruction as reported by the participant via monthly interview questions or call to a pager if symptoms of recurrent biliary obstruction developed. Participants not experiencing recurrent biliary obstruction were censored at the date of last follow-up or date of death.

Time frame: Median follow-up of 125 days in the uncovered SEMS arm and 201 days in the partially covered SEMS arm

Secondary Outcomes

Patient Survival

Patient survival is defined as the date of the placement of the stent to the date of death. Participants lost to follow-up were analyzed in an intention-to-treat fashion and censored at the time of their last follow-up interview.

Time frame: Median follow-up of 125 days in the uncovered SEMS arm and 201 days in the partially covered SEMS arm

Number of Participants With Serious Adverse Events (SAEs)

Serious adverse events were defined as adverse events requiring an invasive procedure or hospitalization or resulting in death.

Time frame: From time of stent placement to participant death or lost to follow-up (up to 1302 days)

Number of Participants With Recurrent Biliary Obstruction Reported by Mechanism

Mechanisms of recurrent biliary obstructions are defined as tumor ingrowth, tumor overgrowth, stent migration, sludge, food debris, stent failed to expand and unknown. Stents may be obstructed by more than one mechanism, therefore, the total does not add up to the number of stent obstructions in each group.

Time frame: Median follow-up of 125 days in the uncovered SEMS arm and 201 days in the partially covered SEMS arm

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.